Doximity (DOCS) Stock Forecast & Price Target

Doximity Inc. reported a 10% year-over-year increase in revenues for FY3Q26, totaling $185.1 million, exceeding both previous guidance and consensus estimates, which reflects strong performance and demand within its digital platform for U.S. medical professionals. The company demonstrated notable growth among its existing customer base, particularly with the top 20 clients, and saw a 10% year-over-year increase in the number of clients spending over $500,000 annually. Additionally, record engagement metrics, including an uptick in unique active users and high growth in multi-module offerings, further underscore Doximity's robust standing and potential for continued expansion in the healthcare technology market.

Doximity Inc. has experienced a decline in gross margins, dropping to 91.5%, which is a decrease both sequentially and year-over-year, indicating potential challenges in maintaining profitability. The company's forecast for FYQ4 FY2026 is disappointing, reflecting only approximately 4% year-over-year growth, primarily due to industry-wide policy headwinds impacting pharma clients’ budgeting. Furthermore, net revenue retention (NRR) metrics for its top 20 customers have also decreased to 112%, signaling a slowdown in client engagement and further contributing to a negative outlook for the stock.